Business
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potent
About this update from Newamsterdam Pharma Company N.v.
NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the National Lipid Association (NLA) 2026 Scientific Sessions, taking place on June 11 – 14, 2026 in Chicago, Illinois. Presentation details are as follows: Title: Novel Cholesterol Lowering Drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?Abstract Number: 353Date and Time: Friday, June 12, 2026 at 3:50 PM CDTLocation: Kiosk #35Presenter: Charles Shear Title: Mediation Analysis on LDL-C and LPa from Pooled Broadway and Brooklyn MACE DataAbstract Number: 220Date and Time: Friday, June 12, 2026 at 10:30 AM CDTLocation: Kiosk #35Presenter: Michael Szarek, Ph.D. Title: Safety of Obicetrapib: An Integrated Phase III Safety AnalysisAbstract Number: 165Date and Time: Friday, June 12, 2026 at 10:30 AM CDTLocation: Kiosk #4Presenter: Adam J. Nelson, Ph.D. Title: CETP Inhibition With Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results From the BROADWAY TrialAbstract Number: 182Date and Time: Friday, June 12, 2026 at 1:50 PM CDTLocation: Kiosk #40Presenter: Liffert Vogt, M.D., Ph.D. Title: Pharmacokinetics and Safety of Obicetrapib in Moderate Hepatic Impairment: Phase I Study ResultsAbstract Number: 249Date and Time: Friday, June 12, 2026 at 3:50 PM CDTLocation: Kiosk #4Presenter: John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer, NewAmsterdam Pharma Title: Obicetrapib CETP inhibition remodels HDL2 and raises ApoM, S1P, ApoA1 monomers, boosting plasma xanthophyll and carotenoid levelsAbstract Number: 251Date and Time: Friday, June 12, 2026 at 1:50 PM CDTLocation: Kiosk #55Presenter: Eric J. Niesor, Ph.D. Title: Cardiovascular Events in People with Normal Low-Density Lipoprotein Cholesterol Levels but Discordantly High Levels of Small/Medium LDL ParticlesAbstract Number: 262Date and Time...
View stock analysis, news, and events for Newamsterdam Pharma Company N.v.